UA77645C2 - Use of escitalopram in treatment of generalised anxiety disorder - Google Patents

Use of escitalopram in treatment of generalised anxiety disorder Download PDF

Info

Publication number: UA77645C2
Authority: UA; Ukraine
Prior art keywords: escitalopram; test; treatment; anxiety disorder; rats
Prior art date: 1999-07-08

Application number

UA2001128286A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-08

Filing date

2000-07-07

Publication date

2007-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA77645(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-07-07 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2007-01-15 Publication of UA77645C2 publication Critical patent/UA77645C2/uk

Links

229960004341 escitalopram Drugs 0.000 title abstract description 10
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title abstract description 10
208000011688 Generalised anxiety disease Diseases 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract description 8
239000003814 drug Substances 0.000 abstract description 6
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 abstract description 5
208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract description 4
229960001653 citalopram Drugs 0.000 abstract description 4
206010033664 Panic attack Diseases 0.000 abstract description 3
208000019906 panic disease Diseases 0.000 abstract description 3
206010029333 Neurosis Diseases 0.000 abstract description 2
208000015238 neurotic disease Diseases 0.000 abstract description 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010041250 Social phobia Diseases 0.000 abstract 1
208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
238000012360 testing method Methods 0.000 description 25
241000700159 Rattus Species 0.000 description 14
238000011160 research Methods 0.000 description 12
230000000694 effects Effects 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
238000000034 method Methods 0.000 description 8
238000002474 experimental method Methods 0.000 description 6
230000035939 shock Effects 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
229940079593 drug Drugs 0.000 description 5
206010036067 polydipsia Diseases 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920005439 Perspex® Polymers 0.000 description 4
230000000949 anxiolytic effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000005192 partition Methods 0.000 description 4
239000004926 polymethyl methacrylate Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000005303 weighing Methods 0.000 description 3
229920004011 Macrolon® Polymers 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002426 anti-panic effect Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000009194 climbing Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
238000009837 dry grinding Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
229960005086 escitalopram oxalate Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012549 training Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000001238 wet grinding Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

UA2001128286A 1999-07-08 2000-07-07 Use of escitalopram in treatment of generalised anxiety disorder UA77645C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA199900991		1999-07-08
PCT/DK2000/000377 WO2001003694A1 (fr)	1999-07-08	2000-07-07	Traitement de troubles nevrotiques

Publications (1)

Publication Number	Publication Date
UA77645C2 true UA77645C2 (en)	2007-01-15

Family

ID=8099796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001128286A UA77645C2 (en)	1999-07-08	2000-07-07	Use of escitalopram in treatment of generalised anxiety disorder

Country Status (38)

Country	Link
US (6)	US7271194B2 (fr)
EP (4)	EP1440691A3 (fr)
JP (1)	JP4773011B2 (fr)
KR (1)	KR100604176B1 (fr)
CN (1)	CN1198610C (fr)
AR (1)	AR021155A1 (fr)
AT (1)	ATE339955T1 (fr)
AU (6)	AU782514B2 (fr)
BG (4)	BG110466A (fr)
BR (1)	BR0011578A (fr)
CA (4)	CA2687392A1 (fr)
CL (3)	CL2008003938A1 (fr)
CO (1)	CO5190674A1 (fr)
CY (1)	CY1105806T1 (fr)
CZ (1)	CZ200270A3 (fr)
DE (1)	DE60030861T2 (fr)
DK (1)	DK1200081T3 (fr)
EA (1)	EA006555B1 (fr)
ES (1)	ES2272298T3 (fr)
HK (1)	HK1048069B (fr)
HR (1)	HRP20010820A2 (fr)
HU (1)	HUP0201791A3 (fr)
IL (5)	IL146131A0 (fr)
IS (1)	IS6137A (fr)
ME (2)	ME00032B (fr)
MX (1)	MXPA01011626A (fr)
MY (1)	MY143278A (fr)
NO (4)	NO329021B1 (fr)
PL (1)	PL352030A1 (fr)
PT (1)	PT1200081E (fr)
SI (1)	SI1200081T1 (fr)
SK (1)	SK82002A3 (fr)
TR (4)	TR200402276T2 (fr)
TW (1)	TWI232101B (fr)
UA (1)	UA77645C2 (fr)
WO (1)	WO2001003694A1 (fr)
YU (1)	YU78701A (fr)
ZA (1)	ZA200108856B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR021155A1 (es)	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
GB0005477D0 (en)	2000-03-07	2000-04-26	Resolution Chemicals Limited	Process for the preparation of citalopram
IL153988A0 (en)	2000-07-21	2003-07-31	Lundbeck & Co As H	Novel compounds and their use as glycine transport inhibitors
KR20040030609A (ko) *	2001-05-01	2004-04-09	하. 룬트벡 아크티에 셀스카브	경상이성체성 순수 에스시탈로프람의 용도
EP1414435B1 (fr)	2001-07-31	2005-01-12	H. Lundbeck A/S	Composition cristalline renfermant de l'escitalopram
AU2003237524A1 (en) *	2002-07-08	2004-01-23	University Of Florida	Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
DE60319739T2 (de) *	2002-12-23	2008-07-17	H. Lundbeck A/S, Valby	Escitalopramhydrobromid und ein verfahren zu dessen herstellung
US20050137255A1 (en) *	2002-12-23	2005-06-23	H. Lundbeck A/S	Crystalline escitalopram hydrobromide and methods for preparing the same
TR200504022T1 (tr) *	2003-03-24	2006-08-21	Hetero Drugs Limited	(S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) *	2003-07-02	2009-04-09	Astrazeneca Ab	Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) *	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (fr) *	2003-12-02	2011-01-12	PharmaNeuroBoost N.V.	Utilisation d'une faible dose de pipamperone et d'un deuxième agent actif dans le traitement des maladies neurodégénératives
US7855195B2 (en) *	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0617382A2 (pt)	2005-10-14	2017-07-11	H Lundbeck As	Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento
US20070134322A1 (en) *	2005-12-14	2007-06-14	Forest Laboratories, Inc.	Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) *	2007-02-07	2009-04-17	Sanofi Aventis Sa	Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) *	2006-07-31	2008-04-16	Sanofi Aventis	Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1143703A (fr) *	1965-03-18
GB1526331A (en) *	1976-01-14	1978-09-27	Kefalas As	Phthalanes
US4439545A (en)	1981-11-19	1984-03-27	Societe D "Expansion Scientifique "Expansia"	Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) *	1984-08-06	1984-09-12	Lundbeck & Co As H	Intermediate compound and method
GB8607313D0 (en) *	1986-03-25	1986-04-30	Ici Plc	Pharmaceutical compositions
GB8814057D0 (en)	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US4902710A (en) *	1988-12-14	1990-02-20	Eli Lilly And Company	Serotonin and norepinephrine uptake inhibitors
US5114976A (en) *	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline
US5296507A (en) *	1990-09-06	1994-03-22	H.Lundbeck A/S	Treatment of cerbrovascular disorders
DK213290D0 (da) *	1990-09-06	1990-09-06	Lundbeck & Co As H	Treatment of cerebrovascular disorders
US5708035A (en) *	1991-02-04	1998-01-13	Sepracor Inc.	Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (fr)	1991-04-16	1992-10-29	National Institutes Of Health	Procede de traitement de la trichotillomanie et de l'onychophagie
DE69233124T2 (de)	1991-11-15	2004-02-19	Sepracor Inc., Marlborough	Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne
EP0714663A3 (fr)	1994-11-28	1997-01-15	Lilly Co Eli	Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5627196A (en) *	1995-01-17	1997-05-06	Eli Lilly And Company	Compounds having effects on serotonin-related systems
AU4918796A (en) *	1995-02-10	1996-08-27	Eli Lilly And Company	Methods of treating or preventing psychiatric disorders
US5554383A (en) *	1995-04-06	1996-09-10	Trustees Of Tufts College	Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) *	1995-04-27	1995-04-27	Astra Ab	A new combination
AU6776196A (en)	1995-08-16	1997-03-12	Eli Lilly And Company	Potentiation of serotonin response
US5846982A (en) *	1996-06-14	1998-12-08	Eli Lilly And Company	Inhibition of serotonin reuptake
US5912256A (en) *	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5747494A (en) *	1996-06-28	1998-05-05	U C B S.A.	Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) *	1996-08-16	1999-09-28	Eli Lilly And Company	Potentiation of serotonin response
ZA977967B (en) *	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses
US5776969A (en) *	1997-02-27	1998-07-07	Eli Lilly And Company	Treatment of sleep disorders
US6069177A (en) *	1997-07-08	2000-05-30	The Hong Kong University Of Science And Technology	3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) *	1997-09-18	1997-09-18	Astra Ab	New compounds
SE9703375D0 (sv) *	1997-09-18	1997-09-18	Astra Ab	A new combination
EP1042310B1 (fr) *	1997-11-11	2002-07-31	H. Lundbeck A/S	Procédé de préparation de citaloprame
DE69903992T2 (de) *	1998-04-15	2003-08-21	Pfizer Prod Inc	Heterocyclische Carboxamide
EP1100501A4 (fr) *	1998-06-30	2002-12-04	Lilly Co Eli	Pyrrolidine et derives de pyrrolidine influen ant les systemes associes a la serotonine
AU771252B2 (en)	1998-07-13	2004-03-18	Nps Pharmaceuticals, Inc.	Methods and compounds for treating depression and other disorders
US6579899B1 (en)	1998-07-16	2003-06-17	Massachusetts Institute Of Technology	Composition for treatment of stress
CA2337507A1 (fr)	1998-07-16	2000-01-27	Massachusetts Institute Of Technology	Composition pour le traitement du stress
US6150376A (en) *	1998-08-05	2000-11-21	Georgetown University	Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv)	1998-09-16	1998-09-16	Astra Ab	A new composition
SE9803158D0 (sv) *	1998-09-16	1998-09-16	Astra Ab	A new composition
ES2189502T3 (es) *	1998-10-20	2003-07-01	Lundbeck & Co As H	Metodo para la prevencion de citalopram.
AR021509A1 (es) *	1998-12-08	2002-07-24	Lundbeck & Co As H	Derivados de benzofurano, su preparacion y uso
PT1173431E (pt) *	1999-04-14	2003-09-30	Lundbeck & Co As H	Metodo de preparacao do citalopram
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
US6333357B1 (en) *	1999-11-05	2001-12-25	Be Able, Llc	Behavior chemotherapy
UA77650C2 (en) *	1999-12-06	2007-01-15	Lundbeck & Co As H	Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
JP2003531169A (ja) *	2000-04-24	2003-10-21	アリックスセラピューティクス	うつ病治療のための材料と方法
JP2002361405A (ja) *	2000-09-25	2002-12-18	Showa Denko Kk	熱交換器の製造方法
KR20040030609A (ko) *	2001-05-01	2004-04-09	하. 룬트벡 아크티에 셀스카브	경상이성체성 순수 에스시탈로프람의 용도

2000
- 2000-07-06 AR ARP000103442A patent/AR021155A1/es unknown
- 2000-07-07 ME MEP-2008-25A patent/ME00032B/fr unknown
- 2000-07-07 AT AT00943692T patent/ATE339955T1/de active
- 2000-07-07 CO CO00051031A patent/CO5190674A1/es not_active Application Discontinuation
- 2000-07-07 EP EP04007522A patent/EP1440691A3/fr not_active Withdrawn
- 2000-07-07 JP JP2001508974A patent/JP4773011B2/ja not_active Expired - Lifetime
- 2000-07-07 WO PCT/DK2000/000377 patent/WO2001003694A1/fr active Application Filing
- 2000-07-07 MY MYPI20003122A patent/MY143278A/en unknown
- 2000-07-07 MX MXPA01011626A patent/MXPA01011626A/es not_active Application Discontinuation
- 2000-07-07 EA EA200200137A patent/EA006555B1/ru not_active IP Right Cessation
- 2000-07-07 PL PL00352030A patent/PL352030A1/xx not_active Application Discontinuation
- 2000-07-07 KR KR1020017016006A patent/KR100604176B1/ko not_active IP Right Cessation
- 2000-07-07 SI SI200030910T patent/SI1200081T1/sl unknown
- 2000-07-07 CA CA2687392A patent/CA2687392A1/fr not_active Abandoned
- 2000-07-07 TR TR2004/02276T patent/TR200402276T2/xx unknown
- 2000-07-07 PT PT00943692T patent/PT1200081E/pt unknown
- 2000-07-07 TR TR2004/02275T patent/TR200402275T2/xx unknown
- 2000-07-07 TR TR2004/02277T patent/TR200402277T2/xx unknown
- 2000-07-07 EP EP04007520A patent/EP1440689A3/fr not_active Withdrawn
- 2000-07-07 ES ES00943692T patent/ES2272298T3/es not_active Expired - Lifetime
- 2000-07-07 BR BR0011578-9A patent/BR0011578A/pt active Search and Examination
- 2000-07-07 EP EP00943692A patent/EP1200081B1/fr not_active Revoked
- 2000-07-07 AU AU58061/00A patent/AU782514B2/en not_active Expired
- 2000-07-07 CA CA002373757A patent/CA2373757C/fr not_active Expired - Lifetime
- 2000-07-07 HU HU0201791A patent/HUP0201791A3/hu unknown
- 2000-07-07 ME MEP-25/08A patent/MEP2508A/xx unknown
- 2000-07-07 EP EP04007521A patent/EP1440690A3/fr not_active Withdrawn
- 2000-07-07 TR TR2002/00014T patent/TR200200014T2/xx unknown
- 2000-07-07 CA CA2687396A patent/CA2687396A1/fr not_active Abandoned
- 2000-07-07 SK SK8-2002A patent/SK82002A3/sk not_active Application Discontinuation
- 2000-07-07 UA UA2001128286A patent/UA77645C2/uk unknown
- 2000-07-07 CN CNB008100292A patent/CN1198610C/zh not_active Expired - Lifetime
- 2000-07-07 IL IL14613100A patent/IL146131A0/xx unknown
- 2000-07-07 DE DE60030861T patent/DE60030861T2/de not_active Expired - Lifetime
- 2000-07-07 DK DK00943692T patent/DK1200081T3/da active
- 2000-07-07 CZ CZ200270A patent/CZ200270A3/cs unknown
- 2000-07-07 CA CA2687394A patent/CA2687394A1/fr not_active Abandoned
- 2000-07-07 YU YU78701A patent/YU78701A/sh unknown
- 2000-07-28 TW TW089115110A patent/TWI232101B/zh not_active IP Right Cessation
2001
- 2001-10-23 IL IL146131A patent/IL146131A/en active IP Right Grant
- 2001-10-26 ZA ZA200108856A patent/ZA200108856B/xx unknown
- 2001-10-30 IS IS6137A patent/IS6137A/is unknown
- 2001-11-06 HR HR20010820A patent/HRP20010820A2/hr not_active Application Discontinuation
- 2001-12-12 US US10/021,126 patent/US7271194B2/en not_active Expired - Lifetime
2002
- 2002-01-04 BG BG11046609A patent/BG110466A/bg unknown
- 2002-01-04 BG BG11046809A patent/BG110468A/bg unknown
- 2002-01-04 BG BG11046709A patent/BG110467A/bg unknown
- 2002-01-04 BG BG106279A patent/BG106279A/bg unknown
- 2002-01-07 NO NO20020062A patent/NO329021B1/no not_active IP Right Cessation
2003
- 2003-01-09 HK HK03100231.6A patent/HK1048069B/zh not_active IP Right Cessation
- 2003-08-07 US US10/637,822 patent/US20040029958A1/en not_active Abandoned
- 2003-08-07 US US10/637,820 patent/US7265151B2/en not_active Expired - Lifetime
- 2003-08-07 US US10/637,821 patent/US20040029957A1/en not_active Abandoned
- 2003-08-20 US US10/644,143 patent/US6960613B2/en not_active Expired - Lifetime
2005
- 2005-06-20 AU AU2005202685A patent/AU2005202685B2/en not_active Ceased
- 2005-06-20 AU AU2005202686A patent/AU2005202686B2/en not_active Expired
- 2005-06-20 AU AU2005202684A patent/AU2005202684B2/en not_active Ceased
- 2005-08-09 IL IL170192A patent/IL170192A/en unknown
- 2005-08-09 IL IL170194A patent/IL170194A/en unknown
- 2005-08-09 IL IL170193A patent/IL170193A/en unknown
2006
- 2006-11-27 CY CY20061101706T patent/CY1105806T1/el unknown
2007
- 2007-08-10 US US11/837,317 patent/US20070276035A1/en not_active Abandoned
2008
- 2008-12-24 AU AU2008264182A patent/AU2008264182A1/en not_active Withdrawn
- 2008-12-24 AU AU2008264188A patent/AU2008264188A1/en not_active Withdrawn
- 2008-12-30 CL CL2008003938A patent/CL2008003938A1/es unknown
- 2008-12-30 CL CL2008003939A patent/CL2008003939A1/es unknown
- 2008-12-30 CL CL2008003941A patent/CL2008003941A1/es unknown
2010
- 2010-03-10 NO NO20100335A patent/NO20100335L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100334A patent/NO20100334L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100333A patent/NO20100333L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20020015346A (ko)	2002-02-27
TR200402277T2 (tr)	2005-01-24
TR200200014T2 (tr)	2002-05-21
CL2008003939A1 (es)	2009-06-05
PL352030A1 (en)	2003-07-28
EA200200137A1 (ru)	2002-06-27
CN1198610C (zh)	2005-04-27
EP1200081A1 (fr)	2002-05-02
CN1360501A (zh)	2002-07-24
BR0011578A (pt)	2002-03-26
DE60030861D1 (de)	2006-11-02
CZ200270A3 (cs)	2002-04-17
NO329021B1 (no)	2010-07-26
PT1200081E (pt)	2007-01-31
AU782514B2 (en)	2005-08-04
SK82002A3 (en)	2002-07-02
NO20100334L (no)	2002-01-07
NO20100333L (no)	2002-01-07
MY143278A (en)	2011-04-15
BG110468A (en)	2010-01-29
CA2687394A1 (fr)	2001-01-18
MXPA01011626A (es)	2002-06-04
IL146131A (en)	2007-02-11
BG106279A (bg)	2002-08-30
NO20020062D0 (no)	2002-01-07
TWI232101B (en)	2005-05-11
EA006555B1 (ru)	2006-02-24
CY1105806T1 (el)	2011-02-02
CA2687392A1 (fr)	2001-01-18
EP1440690A3 (fr)	2004-08-18
AU5806100A (en)	2001-01-30
NO20100335L (no)	2002-01-07
US20070276035A1 (en)	2007-11-29
AU2005202686B2 (en)	2009-01-15
IS6137A (is)	2001-10-30
ZA200108856B (en)	2002-12-24
ATE339955T1 (de)	2006-10-15
BG110466A (en)	2010-01-29
IL146131A0 (en)	2002-07-25
WO2001003694A1 (fr)	2001-01-18
US20040029958A1 (en)	2004-02-12
IL170192A (en)	2010-04-29
HRP20010820A2 (en)	2003-08-31
US7265151B2 (en)	2007-09-04
US20040029957A1 (en)	2004-02-12
JP4773011B2 (ja)	2011-09-14
AU2005202686A1 (en)	2005-07-14
ES2272298T3 (es)	2007-05-01
HK1048069B (zh)	2005-12-16
US20050101665A1 (en)	2005-05-12
TR200402275T2 (tr)	2005-03-21
US20020086899A1 (en)	2002-07-04
AU2005202685B2 (en)	2009-01-15
EP1440691A2 (fr)	2004-07-28
DK1200081T3 (da)	2006-12-27
CA2373757A1 (fr)	2001-01-18
IL170193A (en)	2010-04-29
US20040029956A1 (en)	2004-02-12
KR100604176B1 (ko)	2006-07-25
BG110467A (en)	2010-01-29
AU2005202685A1 (en)	2005-07-14
CO5190674A1 (es)	2002-08-29
AU2005202684A1 (en)	2005-07-14
JP2003504332A (ja)	2003-02-04
TR200402276T2 (tr)	2005-01-24
EP1440689A3 (fr)	2004-08-25
DE60030861T2 (de)	2007-05-03
HK1048069A1 (en)	2003-03-21
MEP2508A (xx)	2010-02-10
AU2005202684B2 (en)	2009-01-15
IL170194A (en)	2010-05-31
EP1200081B1 (fr)	2006-09-20
YU78701A (sh)	2004-03-12
AU2008264188A1 (en)	2009-05-07
US6960613B2 (en)	2005-11-01
EP1440690A2 (fr)	2004-07-28
AR021155A1 (es)	2002-06-12
NO20020062L (no)	2002-01-07
SI1200081T1 (sl)	2007-02-28
CL2008003941A1 (es)	2009-05-22
EP1440689A2 (fr)	2004-07-28
AU2008264182A1 (en)	2009-01-29
CA2373757C (fr)	2010-01-05
HUP0201791A3 (en)	2005-02-28
ME00032B (fr)	2010-02-10
US7271194B2 (en)	2007-09-18
CA2687396A1 (fr)	2001-01-18
EP1440691A3 (fr)	2004-08-25
CL2008003938A1 (es)	2009-05-22
HUP0201791A2 (en)	2002-10-28

Publication	Publication Date	Title
UA77645C2 (en)	2007-01-15	Use of escitalopram in treatment of generalised anxiety disorder
RU2338533C1 (ru)	2008-11-20	СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
KR101574817B1 (ko)	2015-12-04	스테비아 추출물 또는 스테비아 추출물 구성성분을 함유하는 신규한 기능식품 조성물 및 이의 용도
US20100152225A1 (en)	2010-06-17	Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome
CN105142623A (zh)	2015-12-09	用于改善认知功能的方法和组合物
US20210161886A1 (en)	2021-06-03	Methods of treating depressive disorders
EA008372B1 (ru)	2007-04-27	Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
EA008373B1 (ru)	2007-04-27	Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом